Get the Stockscreener App
4.72
1.46%
-0.07
After Hours:
4.70
-0.02
-0.42%
Nuvation Bio Inc stock is traded at $4.72, with a volume of 4.20M.
It is down -1.46% in the last 24 hours and down -7.81% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$4.79
Open:
$4.83
24h Volume:
4.20M
Relative Volume:
0.95
Market Cap:
$1.64B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-11.02
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
+9.26%
1M Performance:
-7.81%
6M Performance:
-32.47%
1Y Performance:
+109.78%
1-Day Range:
$4.63
$4.89
1-Week Range:
$4.07
$4.89
52-Week Range:
$1.57
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.72 | 1.67B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Truist Securities Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation - MSN
Nuvation Bio (NUVB) Collaborates with Thermo Fisher - Insider Monkey
Nuvation Bio rises as B. Riley starts at Buy on launch trajectory for lead drug - MSN
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
NUVB: All proposals passed, including director elections and auditor ratification, with strong quorum - TradingView
Nuvation bid to expand Ibtrozi label undergoes FDA review - MSN
NUVB: IBTROZI and safusidenib drive growth, with new DDC platform updates and strong financial runway - TradingView
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps - Yahoo Finance
Are options traders betting on a big move in Nuvation Bio stock? - MSN
Earnings call transcript: Nuvation Bio Q1 2026 revenue beats forecast, stock jumps - Investing.com Nigeria
David Abrams's Nuvation Bio Inc(NUVB) Holding History - GuruFocus
Nuvation Bio Inc. (NUVB) reports next week: Wall Street expects earnings growth - MSN
Nuvation Bio Completes IBTROZI Manufacturing Tech Transfer to Thermo Fisher - Contract Pharma
Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment - Moomoo
Nuvation Bio stock (US55043Q1004): Manufacturing deal with Thermo Fisher for lung cancer drug - AD HOC NEWS
Nuvation Bio To Collaborate With Thermo Fisher Scientific For U.S.-Based Manufacturing Of Ibtrozi For Ros1-Positive Non-Small Cell Lung Cancer - TradingView
Nuvation Bio partners with Thermo Fisher for US drug manufacturing By Investing.com - Investing.com South Africa
Nuvation Bio partners with Thermo Fisher for US drug manufacturing - Investing.com
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
NUVB: ZUSDURI’s rapid growth and durable results drive expansion, with a robust pipeline fueling future opportunities - TradingView
Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes? - Insider Monkey
10 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement f - The National Law Review
Hot Picks: Biotech stocks gain on cancer drugs and trial data - BNN Bloomberg
A Look At Nuvation Bio (NUVB) Valuation After Profit Shift And Taletrectinib FDA And Guideline Milestones - Sahm
Nuvation Bio Signals Durable Momentum in Earnings Call - TipRanks
Results: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit - simplywall.st
Nuvation Bio Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
Nuvation Bio Inc. (NUVB) Investor Outlook: Exploring the 156% Potential Upside in Cancer Drug Innovation - DirectorsTalk Interviews
Law firm investigates Nuvation Bio's directors for possible breach of fiduciary duties. - Pluang
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB) - PR Newswire
Nuvation Bio’s cancer drug sNDA accepted by FDA for review - Investing.com UK
Nuvation Bio’s cancer drug sNDA accepted by FDA for review By Investing.com - Investing.com South Africa
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer - Investing News Network
Nuvation Bio Inc. (NUVB) lags Q1 earnings estimates - MSN
Lung cancer drug with 4-year response data gets FDA review - Stock Titan
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
Undervalued Penny Stocks To Watch In May 2026 - simplywall.st
MSN Money - MSN
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress By Investing.com - Investing.com India
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nuvation Bio's CEO and CFO line up four investor webcasts in May - Stock Titan
NUVB Stock Rallies As IBTROZI Drives Surprise Profit - StocksToTrade
Nuvation Bio Inc. 2026 Q1 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
A Quick Look at Today's Ratings for Nuvation Bio(NUVB.US), With a Forecast Between $12 to $20 - Moomoo
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress - Investing.com UK
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):